Weight-Loss Pills Are Here: How Oral GLP-1s Compare to Injections
For years, the strongest obesity medicines came only as weekly injections. That changed in 2026. Foundayo (orforglipron), a once-daily pill from Eli Lilly, is now approved by the FDA for adults with obesity, or overweight with weight-related health problems. It is a small-molecule GLP-1, which means it can be taken any time of day, with no restrictions on food or water. Meanwhile the Wegovy pill (oral semaglutide) passed 3 million US prescriptions in about five months after its January 2026 launch, and more than 80% of those new prescriptions went to people who had never used a GLP-1 before.
Not all pills are the same. Oral semaglutide is a peptide, the same type of molecule as the injection, so it needs special tricks to survive the stomach and usually comes with rules about how to take it. Orforglipron and Structure Therapeutics investigational aleniglipron are small molecules: chemically simpler, far easier to manufacture in huge quantities, and they do not need a refrigerated cold chain. That matters less to you at the pharmacy counter and more to whether there is enough supply for everyone who needs it.
What about results? Injections still lead on raw numbers. Eli Lilly retatrutide, an injection still in development, produced 28.3% average weight loss at 80 weeks in its pivotal trial. Pills land lower but are catching up: in a Phase 2 study, aleniglipron produced about 16.3% placebo-adjusted weight loss at 44 weeks, and it is heading into Phase 3. So the honest trade-off today is convenience and supply versus the highest possible weight loss.
Side effects are broadly similar across the class, mostly nausea and other stomach issues that often ease over time. On cost, the new Medicare GLP-1 Bridge means eligible Medicare Part D members can get Zepbound, Wegovy including the pill, and Foundayo for 50 dollars a month through the end of 2027. If you are weighing a pill against an injection, talk to your doctor about which fits your health, your routine and your coverage. This is general information, not medical advice.